Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

Because the risk of many conditions increases with age, doctors generally recommend more frequent lab testing as you get ...

The American Association for the Study of Liver Diseases and Infectious Diseases Society of America have updated guidance on ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

Staying on top of your health isn’t just about hitting the gym, eating well, or getting the necessary vaccines. It also means ...

The CDC announced that it is changing its childhood vaccination schedule to align with other developed nations.

The Trump administration on Monday overhauled the United States' pediatric vaccine schedule, upending years of scientifically ...

The CDC estimates more than 640,000 adults in the U.S. have chronic hepatitis B. Fifteen to 25% of persons who develop the ...

Dec 16 (Reuters) - The U.S. Centers for Disease Control and Prevention on Tuesday ended a long-standing recommendation that all U.S. newborns receive the hepatitis B vaccine, leaving it instead to ...

For many years, Dr. Dean Blumberg, chief of pediatric infectious diseases at the University of California, Davis, said the Centers for Disease Control and Prevention has been the “voice of reason for ...